Graf Acquisition IV said the SEC has declared its registration statement effective on the proposed merger with NKGen Biotech. The SPAC called an Aug. 30 meeting at 10 a.m. Eastern for shareholders to vote on the deal.
Graf also plans to transfer to the Nasdaq from the NYSE upon completion of the merger.
The target is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer (“NK”) cell therapeutics.
The $160 million deal was announced in April and has a minimum $50 million cash condition to close. Read more.
